These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33635154)

  • 1. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
    Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
    Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
    Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
    Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
    Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
    Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
    Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
    Guevara C; Garrido C; Martinez M; Farias GA; Orellana P; Soruco W; Alarcón P; Diaz V; Silva C; Kempton MJ; Barker G; de Grazia J
    Front Neurol; 2019; 10():788. PubMed ID: 31396148
    [No Abstract]   [Full Text] [Related]  

  • 15. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
    Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
    Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
    Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
    Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Uher T; Havrdova EK; Benkert P; Bergsland N; Krasensky J; Srpova B; Dwyer M; Tyblova M; Meier S; Vaneckova M; Horakova D; Zivadinov R; Leppert D; Kalincik T; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2001-2013. PubMed ID: 34612753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.